Clinical trials: Placebo-Pre
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.
- Trial name
- DELIVER (NCT04418765)
- Testing
- Eptinezumab
- Where
- 138 sites in United States, Belgium and 15 more
- Volunteers
- 892 people
- Sponsor
- H. Lundbeck A/S
Gastrointestinal Stromal Tumors
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors…
- Trial name
- GRID (NCT01271712)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best supportive care
- Where
- 57 sites in United States, Austria and 15 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Breast Cancer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label…
- Trial name
- NCT03671330
- Testing
- Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin
- Where
- 24 sites in China
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection
The objectives of this study are: 1. To evaluate the efficacy and safety of two different treatment regimens with BI 201335 (high dose given for 12 weeks or low dose given for 24 weeks both in combination with Pegylated…
- Trial name
- NCT01608737
- Testing
- PegIFN/RBV, BI 201335
- Sponsor
- Boehringer Ingelheim
Prevention of Growth Restriction
Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants
The purpose of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo.
- Trial name
- LAIF (NCT01413581)
- Testing
- rhBSSL (recombinant human bile-salt-stimulated lipase)
- Where
- 49 sites in Belgium, Czechia and 8 more
- Volunteers
- 415 people
- Sponsor
- Swedish Orphan Biovitrum
Metastatic Breast Cancer
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic, HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy, and whose disease has progressed on or after…
- Trial name
- NCT01528345
- Testing
- Dovitinib, Fulvestrant
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response.
- Trial name
- NCT00102336
- Testing
- AMG 531
- Volunteers
- 62 people
- Sponsor
- Amgen
EGFR Inhibitor-associated Rash
Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
This is a clinical research study of an experimental new medication, Menadione Topical Lotion (MTL). The study lotion is experimental and has not been approved for public use.
- Trial name
- NCT00656786
- Testing
- Menadione Topical Lotion
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Primary Disease
Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis
The purpose of this study is to evaluate the efficacy and safety of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season compared with placebo for reduction of…
- Trial name
- NCT00803244
- Testing
- 300 IR
- Where
- 6 sites in France, Italy and 1 more
- Volunteers
- 381 people
- Sponsor
- Stallergenes Greer
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally…
- Trial name
- NCT07066098
- Testing
- IBI343
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Breast Neoplasm
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
- Trial name
- NCT00107016
- Testing
- RAD001, Letrozole 2.5mg, Letrozole 2.5mg
- Where
- 46 sites in United States, Austria and 8 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.
- Trial name
- NCT01387958
- Testing
- LCQ908
- Where
- 2 sites in New Zealand
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by…
- Trial name
- SOLSTICE (NCT04936308)
- Testing
- Guselkumab
- Where
- 169 sites in United States, Argentina and 12 more
- Volunteers
- 453 people
- Sponsor
- Janssen Research & Development, LLC
Nonalcoholic Steatohepatitis
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
- Trial name
- NCT04583423
- Testing
- MK-3655
- Where
- 180 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Merck Sharp & Dohme LLC
Gout
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who are beginning allopurinol treatment for gout.
- Trial name
- NCT00958438
- Testing
- Rilonacept
- Where
- 61 sites in Germany, India and 3 more
- Volunteers
- 248 people
- Sponsor
- Regeneron Pharmaceuticals
Hyperkalemia
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese end-stage renal disease (ESRD) patients on chronic…
- Trial name
- DIALIZE China (NCT04217590)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 36 sites in China
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
PreDiabetes
Effect of Protein Hydrolysates on HbA1c Levels in Pre-diabetics
To evaluate the effectiveness of three different daily doses of plant protein hydrolysates versus placebo, when consumed over a 12-week period, at reducing and maintaining glycated haemoglobin (HbA1c) levels in a pre-diabetic…
- Trial name
- NCT03083600
- Testing
- Plant-based Protein Hydrolysate 1, Plant-based Protein Hydrolysate 2
- Where
- Ireland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials